• Azzato EM, Chen RA, Wacholder S, Chanock SJ, Klebanoff MA, Caporaso NE. (2010) Maternal EPHX1 polymorphisms and risk of phenytoin-induced congenital malformations. Pharmacogenet Genomics20:5863.
  • Cunnington MC, Weil JG, Messenheimer JA, Ferber S, Yerby M, Tennis P. (2011) Final results from 18 years of the International Lamotrigine Pregnancy Registry. Neurology76:18171823.
  • de Wals P, Mastroiacovo P, Weatherall JAC, Lechat M. (1984) EUROCAT guide 1. For the registration of congenital anomalies. European Union, Brussels.
  • Dean JC, Moore SJ, Osborne A, Howe J, Turnpenny PD. (1999) Fetal anticonvulsant syndrome and mutation in the maternal MTHFR gene. Clin Genet56:216220.
  • Dean JCS, Hailey H, Moore SJ, Lloyd DJ, Turnpenny PD, Little J. (2002) Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Genet39:251259.
  • Hernández-Díaz S, Smith CR, Shen A, Mittendorf R, Hauser WA, Yerby M, Holmes LB; For the North American AED Pregnancy Registry; North American AED (Antiepileptic Drug) Pregnancy Registry; Scientific Advisory Committee; North American AED Pregnancy Registry. (2012) Comparative safety of antiepileptic drugs during pregnancy. Neurology78:16921699.
  • Holmes LB, Harvey EA, Coull BA, Huntington KB, Khoshbin S, Hayes AM, Ryan LM. (2001) The teratogenicity of anticonvulsant drugs. N Engl J Med344:11321138.
  • Holmes LB, Mittendorf R, Shen A, Smith CR, Hernandez-Diaz S. (2011) Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Arch Neurol68:12751281.
  • Hunt S, Russell A, Smithson WH, Parsons L, Robertson I, Waddell R, Irwin B, Morrison PJ, Morrow J, Craig J; UK Epilepsy and Pregnancy Register. (2008) Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology71:272276.
  • Kaneko S, Battino D, Andermann R, Wada K, Kan R, Takeda A, Nakane Y, Ogawa Y, Avanzini G, Fumarola C, Granata T, Molteni F, Pardi G, Minotti L, Canger R, Dansky L, Oguni M, Lopes-Cendas I, Sherwin A, Andermann F, Seni MH, Okada M, Teranishi T. (1999) Congenital malformations due to anti-epileptic drugs. Epilepsy Res33:145158.
  • Kini U, Lee R, Jones A, Smith S, Ramsden S, Fryer A, Clayton-Smith J; Liverpool Manchester Neurodevelopmtal Study Group. (2007) Influence of the MTHFR genotype on the rate of malformations following exposure to anti-epileptic drugs in utero. Eur J Med Genet50:411420.
  • Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR; for the SANAD Study group. (2007) The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet369:10161026.
  • Moore SJ, Turnpenny P, Quinn A, Glover S, Lloyd DJ, Montgomery T, Dean JC. (2000) A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet37:489497.
  • Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, Irwin B, McGivern RC, Morrison PJ, Craig J. (2006) Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry77:193198.
  • Olafsson E, Hallgrimsson JT, Hauser WA, Ludvigsson P, Gudmundsson G. (1998) Pregnancies of women with epilepsy: a population-based study in Iceland. Epilepsia39:887892.
  • Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, Perucca E, Vajda F; EURAP study group. (2011) Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol10:609617.
  • Wilson EB. (1927) Probable inference, the law of succession, and statistical inference. J Am Stat Assoc22:209212.